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Abstract: Alzheimer’s disease (AD) is a complex, age-related neurodegenerative disease that
is the most common form of dementia. However, the cure for AD has not yet been founded.
The accumulation of amyloid beta (Aβ) is considered to be a hallmark of AD. Beta-site amyloid
precursor protein cleaving enzyme 1 (BACE1), also known as beta secretase is the initiating enzyme
in the amyloidogenic pathway. Blocking BACE1 could reduce the amount of Aβ, but this would
also prohibit the other functions of BACE1 in brain physiological activity. SPONDIN1 (SPON1) is
known to bind to the BACE1 binding site of the amyloid precursor protein (APP) and blocks the
initiating amyloidogenesis. Here, we show the effect of SPON1 in Aβ reduction in vitro in neural
cells and in an in vivo AD mouse model. We engineered mouse induced neural stem cells (iNSCs) to
express Spon1. iNSCs harboring mouse Spon1 secreted SPON1 protein and reduced the quantity of
Aβ when co-cultured with Aβ-secreting Neuro 2a cells. The human SPON1 gene itself also reduced
Aβ in HEK 293T cells expressing the human APP transgene with AD-linked mutations through
lentiviral-mediated delivery. We also demonstrated that injecting SPON1 reduced the amount of Aβ
and ameliorated cognitive dysfunction and memory impairment in 5xFAD mice expressing human
APP and PSEN1 transgenes with five AD-linked mutations.
Keywords: Alzheimer’s disease; stem cell-based gene therapy; gene therapy; SPON1; amyloid beta;
HEK 293T cells; beta-secretase; induced neural stem cells
1. Introduction
Alzheimer’s disease (AD) is the most prevalent age-related neurodegenerative disease [1].
There have been many attempts to cure AD [2] but, definitive treatment has yet to be developed [3].
Amyloid beta (Aβ) and hyperphosphorylated tau are major pathological hallmarks of Alzheimer
disease. Several studies showed that inflammatory reactions or neuronal cell death in the AD patient’s
brain occur due to high Aβ accumulation as well as tau pathology [4–7]. Therefore, studies have
focused on reducing the amount of Aβ in the brain to cure AD [8].
One possible therapeutic approach is to target the enzymes that process amyloidogenesis [9]. Aβ is
derived from the amyloid precursor protein (APP) through sequential cleavages by beta-site amyloid
precursor protein cleaving enzyme 1 (BACE1) and γ-secretase [10,11]. Reduction of Aβ through
inhibition of BACE1 has been studied as a way to find a treatment for AD [12–14]. However, BACE1 not
only initiates amyloidogenesis, but also conducts other functions in brain physiological activity, such as
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processing sodium current, synaptic transmission, and myelination [15–17]. Thus, the inhibition of
BACE1 could cause dysfunctions in the brain physiological activities [18–20].
To overcome this limitation, SPONDIN1 (SPON1), also known as F-Spondin has been studied as a
novel therapeutic approach. SPON1 is an extracellular matrix protein, consisting of three domains:
spondin, reelin, and thrombospondin, and plays an essential role in neuronal survival and the migration
of commissural axons [21,22]. SPON1 binds to the BACE1 cleavage site of APP and prohibits APP
from being cleaved and released as the Aβ form [23]. SPON1 also interacts with the apolipoprotein E
receptor ApoEr2 and clusters with APP, resulting in decreased production of Aβ [24]. Even though
SPON1 has the potential to inhibit the amyloidogenic pathway, it has not been widely studied for
AD therapy [25].
To confirm the efficacy of AD therapy, testing on neural cells isolated from patients may show the
efficacy more accurately than testing on neural cell lines [26,27]. However, neural cells are difficult in
isolation from the brain and in large-scale expansion for drug testing [28]. Recently, a direct lineage
conversion was established to generate neural stem cells which proliferate well from fibroblasts by
ectopic expression of transcription factors [29,30].
In this study, we generated mouse induced neural stem cells by the ectopic expression of
Octamer-binding transcription factor 4 (Oct4) and then genetically engineered them to express mouse
Spon1 (iNSC-Spon1). When iNSC-Spon1 was co-cultured with mouse neuroblastoma cells, Neuro
2a cells (N2a) which secrete Aβ, the amount of secreted Aβ was reduced. Next, we administered
lentiviral vector encoding human SPON1 into human HEK-293T, which were engineered to express
human APP with AD-linked mutations, and confirmed that human SPON1 reduced the secretion of Aβ.
To evaluate the effect of human SPON1 gene in mice expressing human APP and PSEN1 transgenes
with five AD-linked mutations (5xFAD), lentiviral-human SPON1 was injected into the hippocampus
and entorhinal cortex (EC) in the early stage of amyloidogenesis. The amount of Aβ was reduced,
and memory and cognition of 5xFAD mice were improved after human SPON1 injection. Therefore,
we showed that SPON1 may be used as a treatment for AD.
2. Materials and Methods
2.1. Cell Culture
Mouse primary dermal fibroblasts were isolated from the back skin of female CF-1 mice (6-week-old,
16–18 g, ORIENT, Seongnam, Gyeonggi, South Korea), as described previously [31]. The mice were
anesthetized with 1–2% isoflurane. Dorsal mouse skin (60 × 100 mm) was harvested using scissors and
minced using razor blades. After incubation with collagenase IV (1 mg/mL) at 37 ◦C for 1 h, the cell
suspension was passed through a 70-µm filter. Primary skin fibroblasts were cultured in DMEM
medium (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco,
Grand Island, NY, USA) and 1% penicillin/streptomycin (Gibco, Grand Island, NY, USA).
iNSCs were derived from mouse skin fibroblasts by transduction of retroviral vectors encoding
mouse Oct4 as previously described [30]. Skin fibroblasts (3 × 104 per well) were seeded on a
6-well plate and incubated with retrovirus containing mouse Oct4 supernatants. Three days after
infection, the medium was replaced with NSC medium, comprising DMEM/F12 medium (Gibco,
Grand Island, NY, USA) supplemented with N2 (Gibco, Grand Island, NY, USA), 2 mM L-Glutamine
(Gibco, Grand Island, NY, USA), 1% penicillin/streptomycin and 10 ng/mL each of FGF-2 (Peprotech)
and EGF (Peprotech). The medium was replaced every 2–3 days.
N2a cells were gifted by Prof. Jeon, Chang-Jin (Kyungpook National University, Daegu, South Korea)
and cultured in DMEM medium (Gibco, Grand Island, NY, USA) supplemented with 10% FBS (Gibco,
Grand Island, NY, USA) and 1% penicillin/streptomycin (Gibco, Grand Island, NY, USA). HEK 293T
cells were purchased from American Type Culture Collection (ATCC, Manassas, Virginia, USA) and
cultured in DMEM medium (Gibco, Grand Island, NY, USA) supplemented with 10% FBS (Gibco,
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Grand Island, NY, USA) and 1% penicillin/streptomycin (Gibco, Grand Island, NY, USA). All cells were
maintained in a humidified atmosphere containing 5% CO2 at 37 ◦C.
2.2. Vector Construction
To construct the lentiviral vector encoding Spon1, mouse Spon1 cDNA sequence encoding amino
acid 1–807 for full length Spon1 was amplified by PCR. Human SPON1 cDNA sequence encoding
amino acid 1–807 for full length SPON1 was amplified by PCR. These mouse Spon1 and human SPON1
PCR products were ligated to a pLVX lentiviral vector encoding the hygromycin resistance gene
(pLVX-Spon1 and pLVX-SPON1 respectively).
To construct the lentiviral vector encoding human APP with AD-linked mutations, the coding
sequence of the human APP transgene with Swedish (K670N/M671L), Florida (I716V), and London
(V717I) mutations was amplified from 5xFAD tail gDNA by PCR. The PCR product was ligated to
pLVX lentiviral vector encoding the puromycin resistance gene (pLVX-APP).
All viral vectors were packaged in HEK 293T cells using x-tremeGENE9 (Roche, Mannheim,
Baden-Württemberg, Germany) according to the manufacturer’s protocols.
2.3. Therapeutic Engineering
iNSCs (5 × 104 cells/well on a 12-well plate) were plated. The next day, the cells were treated with
4 µg/mL protamine sulfate and then incubated with pLVX-Spon1 for 24 h. The infected cells were
selected by 200 µg/mL hygromycin treatment for 2 weeks (iNSC-Spon1).
HEK 293T cells (5 × 104 cells/well on a 12-well plate) were plated. The next day, the cells were
treated with 4 µg/mL protamine sulfate and then infected with pLVX-APP for 24 h. The infected cells
were selected by 1 µg/mL puromycin treatment for 2 weeks (293T-APP).
The integration of the transgene was confirmed by PCR-based genotyping. The cells (1 × 106 cells)
were lysed with 75 µL 50% NaOH at 98 ◦C for 1 h. and neutralized with 75 µL 40mM Tris-HCl. PCR was
performed with 2 uL cell lysate, Taq DNA polymerase mixture (Invitrogen, Carlsbad, CA, USA) and
primers. The primer sequences are listed in Table S1. PCR was performed in the following steps; 94 ◦C
180 s (pre-denaturation), 94 ◦C 45 s (denaturation), 57 ◦C 30 s (annealing), 72 ◦C 90 s (elongation), 72 ◦C
600 s (final elongation). The total cycle number from denaturation to elongation was 35.
2.4. Conventional and Quantitative Real-Time PCR
RNA was extracted by an RNA mini kit (Qiagen, Hilden, North Rhine-Westphalia, Germany)
through the manufacturer’s protocol. RNA was converted into cDNA by MMuLV-reverse transcriptase
(NEB, Ipswich, MA, USA), and 1 µL cDNA was added with SYBR green (Bio-Rad, Hercules, CA, USA)
for qRT-PCR. cDNA was added with Taq DNA polymerase for conventional PCR. The primer sequences
are listed in Table S1.
2.5. Immunocytochemistry
iNSC-Spon1 and 293T-APP-SPON1 cells were fixed by 4% paraformaldehyde for 15 min, and then
1% Triton-X was treated for permeabilization. Next, cells were incubated with 4% FBS for 30 min.
Primary antibodies that were diluted by 4% FBS were added for 1 h at room temperature (RT).
After washing, secondary antibodies (1:1000) diluted in PBS were added for 1 h at RT. Secondary
antibodies included Alexa488 anti-goat antibody (ab150129, abcam, Cambridge, UK), which was used
for V5 and Sox2 staining, and Alexa555 anti-mouse antibody (ab150118, abcam, Cambridge, UK),
which was used for Nestin staining. Cells were counterstained by Hoechst 33,342 (Invitrogen,
Carlsbad, CA, USA). The cells were imaged using a Leica fluorescence microscopy (DMI 3000 B, Leica,
Wetzlar, Hesse, Germany). The primary antibodies are listed in Supplementary Table S2.
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2.6. ELISA
To quantify the secretion of mouse SPON1, 2 × 105 cells of iNSCs or iNSC-Spon1 were seeded
in one well of 6well plate and the media was harvested after 48 h. Mouse SPON1 ELISA (Cusabio,
Wuhan, Hubei, China) was performed according to the manufacturer’s protocol.
To verify Aβ reduction by iNSC-Spon1 through a co-culture system, 2 × 105 cells of iNSCs or
iNSC-Spon1 and 2 × 105 cells of N2a were seeded on the same well of a 6-well plate for 48 h. The media
was harvested and Aβ40 and Aβ42 ELISA assays (Invitrogen, Carlsbad, CA, USA) were performed
according to the manufacturer’s protocol.
To verify Aβ reduction by human SPON1, 2 × 105 cells of 293T and 293T-SPON1 were seeded in
one well of a 6-well plate and the media were harvested after 24 h. Aβ40 and Aβ42 ELISA (Wako,
Chuo-Ku, Osaka, Japan) were performed according to the manufacturer’s protocol.
All ELISA assays were performed in biological triplicate.
2.7. In Vivo Experiments
All animal studies were approved by Ulsan National Institute of Science Institutional Animal
Care and Use Committee (UNISTIACUC-18-04) and carried out in accordance with the Ulsan National
Institute of Science and Technology animal guideline. Animals were housed in an animal care cage
(4–5 per cage) under standard environmental conditions (temperature 20 ± 2 ◦C; humidity 40 ± 5%;
12 h light/dark cycle) and were provided with normal pellet food and water ad labium. 5xFAD mice
were purchased from The Jackson Laboratory (Bar Harbor, ME, USA) and were maintained on a hybrid
C57BL6/SJL background. All surgeries were carried out with sterilized surgical instruments in the clean
animal surgery room of the UNIST in vivo research center (Ulsan, South Korea) during the daytime.
Human SPON1 virus or mKatet2 virus was generated as previously described [32]. The pLVX-SPON1
or pLVX-mKate2 vectors were transfected into HEK cells (5 × 106 cells per plate of a 100-mm plate/total
12 plates). Two days after transfection, the medium was harvested and spun down twice at 80,000× g
for 1.5 h. Virus pellets were resuspended by 130 µL PBS. For surgery, 5xFAD female mice (three months
old, 19–22 g, n = 14) were fixed in a stereotaxic frame (Stoelting, Wood Dale, IL, USA) under anesthesia
with 1–2% isoflurane. The scalp of the mouse was excised and four holes were drilled in the skull
according to coordination (hippocampus: AP: −2.02, ML: ±1.8; entorhinal cortex AP: −4.7, ML: ±2.9).
Human SPON1 virus or mKatet2 virus was stereotactically injected into the hippocampus (AP: −2.02,
ML: ±1.8, DV: −1.9) [33] and entorhinal cortex (AP: −4.7, ML: ±2.9, DV: −3.1) [34] at a rate of 0.5 µL/min
using a Hamilton microsyringe and motorized stereotaxic injector (Stoelting, Wood Dale, IL, USA).
Non-Tg wild-type littermates received a sham surgery as control.
2.8. Morris Water Maze Assay
The Morris water maze (MWM) assay was performed to examine hippocampal-dependent
learning and memory following the standard protocol 6 months after injection [35,36]. We used a
water bath (diameter of 95 cm). The water temperature was 26 ± 1 ◦C. White paint was released in
the water to make the platform (target) invisible to the mice. We attached four different cues on the
interior of the pool at the location of North, South, East, and West above the water surface. The training
for the hidden platform of the MWM assay consisted of four trials each day for 5 days. The mouse
start position is listed in Table S3. The location of the platform was fixed in the South West quadrant.
For the 5 days of training, the mice were trained to find a submerged platform. The training time for
1 trial was 1 min, and the interval between trials was 15 min. If the mouse found the platform before
this time, the time was recorded. The probe trial was performed without the platform for 1 min 24 h
after the last day of the training. During the trials, the mouse’s movement was tracked and analyzed
by SMART software (Version 3.0, Panlab Harvard Apparatus, Barcelona, Spain).
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2.9. Western Blot
Mice were sacrificed by intraperitoneal injection of avertin (300 µL per 10 g of mouse weight)
generated by mixing 2,2,2-tribromoethanol:Tert-amyl alcohol (1:1 ratio) and perfused with PBS after
MWM assay. The brain was extracted and divided into two halves: the right and left cerebral
hemispheres. The right hemisphere was used for western blot. The hippocampus from the right
hemisphere was mechanically dissected. Tissues were homogenized as previously described [37].
The hippocampus was weighted, and 5 times the volume of tissue homogenization buffer (tissue
weigh: buffer volume = 1:5) consisting of 2 mM Tris (Bio-Rad, Hercules, CA), 250 mM sucrose
(Sigma-aldrich, St. Louis, MO, USA), and 0.5 mM EDTA (Sigma-aldrich, St. Louis, MO, USA), 0.5 mM
EGTA (Sigma-aldrich, St. Louis, MO, USA) with a protease inhibitor cocktail (1:100, Sigma-aldrich,
St. Louis, MO, USA) was added into tissues and mechanically homogenized by TissueLyser LT (Qiagen,
Hilden, North Rhine-Westphalia, Germany). The same volume of 0.4% diethylamine (Sigma-aldrich,
St. Louis, MO, USA) was added into the homogenate and it was sonicated it for 1 min. The homogenates
were spun down at 100,000× g for 1 h at 4 ◦C. The supernatant was harvested and quantified by
BCA protein assay. The supernatant (20 µg) was loaded onto an 8–15% gradient polyacrylamide gel
and transferred onto an immune-blot PVDF membrane. The membrane was boiled in PBS for 5 min
and incubated in a blocking solution (6% skim milk, Bio-Rad, Hercules, CA, USA) for 1 h at 4 ◦C.
The membrane was incubated with the primary antibodies diluted in the blocking solution for 16 h at
4 ◦C. After washing, the membrane was incubated with HRP-conjugated secondary antibodies diluted
in the blocking solution. Finally, all protein bands were visualized using chemiluminescence substrates.
The antibodies were listed in Supplementary Table S2. The images were analyzed by ImageJ software.
We selected the rectangle tool in ImageJ and drew a frame around the band as a region of interest
(ROI). The density of every band was measured in the same sized frame. We calculated the ratio of the
density of the Aβ oligomer and HSC-70 ROI.
2.10. Immunohistochemistry
The left hemisphere of the mice sacrificed after the behavior test was used for
immunohistochemistry. The left hemisphere was fixed with 4% paraformaldehyde for 24 h at
4 ◦C, incubated with 30% sucrose for 48 h 4 ◦C and then frozen at −80 ◦C after embedding in optimal
cutting temperature (OCT) compound (Sigma-aldrich, St. Louis, MO, USA) overnight. The specimen
was cryosectioned at a thickness of 30 µm using Cryostat (CM1950, Leica, Buffalo Grove, IL, USA).
The sections were mounted on a saline-coated slide glass. For antigen retrieval, the slide was treated
with 0.1 M sodium citrate with 0.05% Tween-20 and boiled at 120 ◦C for 10 s and at 90 ◦C for
10 min. The slide was cooled at RT for 30min. Then, the slide was permeabilized with 1% triton-X
(Sigma-aldrich, St. Louis, MO, USA) for 10 min and then blocked with 5% FBS for 30min. Primary
antibodies were diluted in 5% FBS and treated in the sections overnight at 4 ◦C. After washing,
secondary antibodies diluted in PBS (1:1000) were treated for 1 h at RT. Secondary antibodies included
Alexa488 anti-goat antibody (ab150129, abcam, Cambridge, England, UK), which was used for V5
staining, and Alexa488 anti-mouse antibody (ab150118, abcam, Cambridge, England, UK), which was
used for Aβ staining. Nuclei on the tissue were counterstained by Hoechst 33,342 (Invitrogen, Carlsbad,
CA, USA). After the whole process, the specimen was covered by a cover glass with a mounting
solution (HIGHDEF IHC mount, Enzo, Farmingdale, NY, USA). The sections were imaged using
Axio Zoom microscopy (Carl Zeiss, Oberkochen, Baden-Württemberg, Germany). Quantification of
hippocampus immunofluorescent images were conducted by ImageJ software [38]. The area percentage
of fluorescence signal brighter than the local threshold was calculated compared to the whole tissue
section area. More than 5 sections from each hemisphere sample with comparable morphology were
selected for quantification. The antibodies are listed in Supplementary Table S2.
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2.11. Statistical Analysis
Statistical analysis was performed with SigmaPlot software (Version 12.0). One-way ANOVA
was used to determine the difference between experimental groups. p < 0.05 and p < 0.001 were
considered significant.
3. Results
3.1. Mouse Induced Neural Stem Cells Expressing Spon1 Maintain Neural Stem Cell Characteristics
To investigate the ability of Spon1 to reduce Aβ of autologous neural cells-mediated gene
therapy, we generated induced neural stem cells (iNSCs) from autologous mouse fibroblasts by ectopic
expression of Oct4 through a direct conversion strategy as previously described [17] (Figure 1A). iNSCs
were genetically engineered to express Spon1 by transduction with a lentiviral vector encoding mouse
Spon1 coding sequence (iNSC-Spon1) (Figure 1B). We confirmed the integration of exogenous Spon1 in
iNSC-Spon1 and expression of exogenous Spon1 in iNSC-Spon1 (Figure 1C,D). We also analyzed the
endogenous Spon1 expression. The expression level of endogenous Spon1 in iNSC-Spon1 was similar
to that of iNSCs (Figure 1E). The expression of exogenous Spon1 was also confirmed at the translational
level by detecting a V5 tag linked to the 3′ terminal Spon1 coding sequence (Figure 1F). To reveal
whether the expression of exogenous Spon1 did not change iNSC characteristics, the expression of
NSC markers Sox2, Pax6, Olig2, and Nestin was confirmed by RT-PCR (Figure 1G). No significant
difference in expression of these NSC markers was observed between iNSCs and iNSC-Spon1.
We also confirmed that Nestin and Sox2 are expressed in iNSC-Spon1 through immunocytochemistry
(Figure 1H). Thus, these results indicated that iNSCs can maintain their characteristics after engineering
to express Spon1.
3.2. Mouse iNSCs Expressing Mouse Spon1 Reduce Amyloid Beta through the Bystander Effect
We confirmed the secretion of mouse SPON1 from iNSC-Spon1 since SPON1 is a secreted protein
(Figure 2A). Mouse SPON1 (230 pg/mL) was detected after 24 h culture. To evaluate the effect of
SPON1 on the production of Aβ40 and Aβ42 peptides, co-cultured media were collected after mouse
Neuro 2a cells (N2a) were co-cultured with either iNSC-Spon1 or iNSCs for 48 h and quantified by
ELISA. Both Aβ40 and Aβ42 concentrations decreased significantly when N2a was co-cultured with
iNSC-Spon1 (49% and 37% compared to co-culture with iNSCs, respectively) (Figure 2B,C).
3.3. Human SPON1 Directly Reduces Amyloid Beta
Next, we evaluated the effect of SPON1 by direct gene delivery. We engineered HEK 293T cells
to express human APP with familial AD mutation by transducing a lentiviral vector encoding APP
with Swedish (K670N/M671L), Florida (I716V), and London (V717I) mutations (293T-APP) (Figure 3A).
293T-APP highly expressed exogenous APP (Figure 3B) and secreted both Aβ40 (4053.9 pmol/L)
and Aβ42 (794.6 pmol/L) (Figure 3C). We infected 293T-APP with a lentiviral vector encoding
human SPON1 (293T-APP-SPON1) (Figure 3D). We observed that exogenous V5-tagged SPON1
was expressed in 293T-APP-SPON1 and also confirmed the gene expression level of exogenous
SPON1 in 293T-APP-SPON1 by qRT-PCR (Figure 3E,F). There was no significant difference in the
expression of genes (APP, BACE1, and PSEN1) related to amyloidogenesis in 293T-APP-SPON1
compared to 293T-APP (Figure 3F). We found that amount of Aβ40 (45%) and Aβ42 (24%) were
lower in 293T-APP-SPON1 compared to 293T-APP (Figure 3H,I) thereby confirming that direct SPON1
expression in 293T-APP affects the Aβ secretion. Thus, these results indicate that human SPON1 is
able to inhibit Aβ production.
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platform location from five days of training. (Figure 4D). Compared to mKate2-injected 5xFAD, 
Figure 3. The reduction of Aβ by direct human SPON1 gene delivery. (A) Schematic drawing of
lentiviral vector encoding the human APP transgene with Swedish (K670N/M671L), Florida (I716V),
and London (V717I) mutations. (B) Quantification of exogenous APP expression in 293T-APP using
qRT-PCR. Data are presented as mean ± SEM (n = 3). (C) The quantification of secreted Aβ 40 and Aβ
42 in 293T-APP cultured medium by ELISA. Data are presented as mean ± SEM (n = 3). (D) Schematic
drawing of lentivi l vector encoding full length of human SPON1 coding sequences. V5 tag was
linked to open reading frame (ORF). (E) Immun fluorescence image of ectopic expression of human
SPON1 in 293T-APP-SPON1. Anti-V5 antibody was used to detect V5-tagged SPON1. Scale bar: 50 µm
(F) Quantification of exogenous SPON1 expression in 293T-APP (No) and 293T-APP-SPON1 (SP) using
qRT-PCR. Data are presented as mean ± SEM (n = 3). (G) The expression of genes related to the
amyloidogenic pathway in 293T-APP (No) and 293T-APP-SPON1 (SP) by qRT-PCR. Data are presented
as mean ± SEM (n = 3). (H,I) The quantification of secreted Aβ 40 (H) and Aβ 42 (I) in 293T-APP and
293T-APP-SPON1 cultured medium by ELISA. The amount of secreted Aβ 40 or Aβ 42 was normalized
to 100% in 293T-APP. Data are pres nted as mean ± SEM (n = 3).
3.4. Human SPON1 Induces Improvement of Learning in the Alzheimer’s Disease Model
To de onstrat that SPON1 improves the cognition f AD model mice, we injected lentiviral
human SPON1 o mKate2 (MOCK control) into both the hippocampus and entorhinal cortex (EC)
of 5xFAD mice (three months old) at an early stage of AD pathological development (Figure 4A,B).
Age-matched, non-transgenic wild-type mice underwent sham surgery as control.
Six months after SPON1 delivery, mice (nine-month-old) were tested for learning and memory
proficiency through the Morris water maze (MWM) assay. All mice were trained for five consecutive
days (Figure 4C). The next day, probe trials were performed to confirm whether mice memorize
the platform location from five days of training. (Figure 4D). Compared to mKate2-injected 5xFAD,
SPON1-injected 5xFAD crossed the platform location often, spent more time in the target quadrant,
and had a shorter mean distance to the target (Figure 4E–G).
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(A) Schematic diagram of the experimental procedures. Intracranial injection of lentiviral vector
encoding human SPON1 coding sequences on 3-month-old mice. When the mice were nine months
old, the behavioral (Morris water maze; MWM) test w s performed. All mice were sacrificed after the
behavioral test. (B) Schematic illustration of the four SPON1 injection sites in the dentate gyrus of the
hippocampus (a) and entorhinal cortex (b). (C) Escape latency in the MWM plotted against the training
days. N number: WT sham 12, 5xFAD SPON1 14, 5xFAD mKate2 11. (D) Illustrative images of mouse
trajectories during 1 min probe trial of the MWM test. The probe trial was performed without a platform
1 day after 5-day training. The platform was c nstantly located in the middle of the South/West during
5-day training. The green dot on the side of the North/East is the start site. The red dot is the last
location of the mouse at the end of the 1-min probe trial. (E) Frequency of platform crossing during the
1-min probe trial of the MWM test. N number: WT sham 12, 5xFAD SPON1 14, 5xFAD mKate2 11.
* indicates p < 0.05 (One-way ANOVA). (F) Percentage of time spent in the target quadrant during the
1-min probe trial of the MWM test. N number: WT sham 12, 5xFAD SPON1 14, 5xFAD mKate2 11.
* indicates p < 0.05 (One-way ANOVA). (G) Mean distance to target during the 1-min probe trial of
the MWM test. N number: WT sham 12, 5xFAD SPON1 14, 5xFAD mKate2 11. * indicates p < 0.05
(One-way ANOVA). (H–J) Aβ expression of 5xFAD by western blot. Western blot with the anti-Aβ
(MOAB-2) antibody using the hippocampus from SPON1 or mKate2-injected 5xFAD (5xFAD SPON1
or 5xFAD mKate2 respectively). Aβ high molecular weight (~50 kDa) oligomers and Aβ (~25 kDa)
oligomer were detected. The density of bands was quantified by imageJ (I,J). V5-tagged SPON1 was
detected by anti-V5 antibody. HSC-70 is shown as a loading control. * indicates p < 0.05 (One-way
ANOVA). (K,L) Representative images of the hippocampus (K) and entorhinal cortex (L) showing Aβ
plaques. Scale bar: 100 µm (M) Quantification of Aβ plaques in the hippocampus. Percentage of green
fluorescence with respect to the area of the picture. * indicates p < 0.05 (One-way ANOVA).
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To determine whether SPON1 has an effect on the inhibition of Aβ production in vivo, we dissected
the SPON1-injected 5xFAD brains and quantified Aβ by western blot. Soluble Aβ oligomers rather than
plaques are known to be more cytotoxic and trigger synapse failure and memory impairment [39,40].
High molecular weight (~50 kDa) Aβ oligomers and 25 kDa Aβ oligomers were significantly reduced
in the hippocampus region of SPON1-injected 5xFAD (Figure 4H–J). SPON1 was only detected in
the SPON1-injected hippocampus. We could observe SPON1 expression only at the injection site
in the hippocampus and EC of the brain section (Supplementary Figure S1). We then conducted
immunostaining of Aβ plaques to see further histological evidence of SPON1 effect. The fluorescence
signal of the SPON1-injected hippocampus and EC has less intensity and coverage of Aβ staining,
compared to MOCK injected group (Figure 4K,L). The SPON1-injected hippocampus has significantly
less Aβ plaques than the MOCK-injected hippocampus (Figure 4M). These data indicate that SPON1
can reduce the Aβ and reverse cognitive impairment in the 5xFAD mouse model of AD.
4. Discussion
In this study, we demonstrated the effects of SPON1 as a treatment option for AD. In particular,
the direct injection of SPON1 into the animal model of AD reduced Aβ levels and improved the
memory function of the mice.
4.1. The Effect of SPON1 on Decreasing Aβ Secretion In Vitro
We observed that SPON1 reduced Aβ levels both in the co-culture of mouse iNSC-Spon1 and
mouse N2a cells and in human SPON1 infection into human 293T-APP cells. Previous research
from Ho et al. showed that SPON1 bound to the extracellular region of APP and inhibited BACE1
cleavage of APP [23]. In our study, Aβ40 and Aβ42 concentration were reduced in the co-culture of
mouse iNSC-Spon1 and mouse N2a cells. This result indicates that the SPON1, which is secreted from
iNSC-Spon1 cells, inhibits Aβ synthesis by binding to APP in the N2a cell membrane. We also confirmed
that iNSC-Spon1 maintains NSC marker gene expression. These results suggest the feasibility of stem
cell-mediated gene therapy of SPON1 for AD patients. The direct conversion method allows to generate
iNSCs from fibroblasts, which can be used for stem cell-mediated gene therapy. Moreover, we showed
that Human SPON1 also prevented the generation of Aβ40 and Aβ42 from human 293T-APP by viral
gene transfer. These results indicate not only the therapeutic potency of human SPON1, but also the
feasibility of human SPON1 gene therapy in AD treatment.
4.2. Aβ Reduction and Reversal of Cognitive Impairment and Memory Dysfunction by Administration of
SPON1 into 5xFAD Mice
We proved that SPON1 injection ameliorated cognitive impairment and memory dysfunction in
AD mice. Hafez et al. performed the behavior test after Spon1 injection on AD mice but could not
prove any improvement in memory and cognition behavior of AD mice [25]. The contradictory result
from Hafez et al. might be the injection time of Spon1. They injected viral Spon1 in 5.5-month-old
AD mice even though Aβ began to deposit at three months of age. So far, one of the reasons
for failure in AD therapies has been that the treatment begins after significant Aβ deposition has
occurred. Recent studies have shown that treatment at an early stage of amyloid pathology was
most effective [41,42]. Treatment with a γ-secretase inhibitor (GSI) for three months at four months of
age resulted in a sustained reduction of amyloid plaque pathology in APP Tg2576 mice compared
to treatment at seven or 12 months of age. Chronic treatments with a BACE1 inhibitor (GRL-8234)
reduced cerebral Aβ42 levels and reversed memory impairments in four-month-old 5XFAD mice.
In contrast, in 12-month-old 5XFAD mice, only marginal reductions of Aβ42 were observed after
GRL-8234 treatment, and their memory function remained impaired. A previous study has shown
that Aβ accumulation was dramatically increased between four and six months in 5xFAD [43]. In our
experiments, virus-mediated SPON1 was injected into young AD mice (three months old) to prevent
Aβ plaque deposition from an early stage of amyloid pathology. We conducted the behavior test with
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nine-month-old mice, six months after SPON1 injection, because previous studies established that
nine-month-old 5xFAD mice showed a significant difference in learning and memory performance
compared to their non-transgenic littermate [44,45].
In addition, Hafez et al. injected mouse Spon1 into AD mice that have human APP transgene,
but we have administered human SPON1 to 5xFAD mice which express human APP transgenes.
Since SPON1 binds to APP, matching the species would be necessary. Moreover, we decided to inject
SPON1 into both the hippocampus and entorhinal cortex (EC) to enhance hippocampal-dependent
memory since the EC forms a neuronal network with the hippocampus and previous studies showed
that brain-derived neurotrophic factor injection into the EC improved the hippocampal-dependent
learning of the AD model [34,46].
Furthermore, we will also investigate the effect of SPON1 on inflammation, neuronal death,
and complement expression, which are phenotypes associated with aging in relatively old AD mice [47].
With the development of next-generation genome sequencing, PET imaging, and blood tests,
AD patients can be diagnosed at an early stage of amyloid pathology [48–50]. SPON1 gene therapy
would be a promising option for AD treatment in early-stage amyloid pathology with the development
of diagnostic technology.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/9/5/1275/s1.
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5xFAD Mouse expressing human APP and PSEN1 transgenes with five AD-linked mutations
Aβ Amyloid beta
AD Alzheimer’s disease
APP Amyloid precursor protein
BACE1 Beta-site amyloid precursor protein cleaving enzyme 1
EC Entorhinal cortex
FBS Fetal bovine serum
iNSCs Induced neural stem cells
iNSC-Spon1 Induced neural stem cells genetically engineered to express mouse Spon1
N2a Neuro 2a cells
OCT Optimal cutting temperature compound
Oct4 Octamer-binding transcription factor 4
ROI Region of interest
SPON1 SPONDIN1, F-Spondin
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